FDA approves Keytruda (pembrolizumab) for treatment of patients with
high-risk early-stage triple-negative breast cancer in combination with
chemotherapy as neoadjuvant treatment, then continued as single agent as
adjuvant treatment after surgery. News release. Merck. July 27, 2021.